5-Methoxy 2-aminoindane

Polyrizon Ltd. has signed a non-binding Letter of Intent with an unnamed psychedelics company to develop innovative intranasal formulations for psychedelic-based treatments.

Clearmind Medicine announced the publication of a patent by the Korean Intellectual Property Office for its innovative MEAI and N-Acylethanolamines combination therapy targeting cocaine addiction.

GH Research's GH001, an inhaled 5-MeO-DMT, met its primary endpoint in a Phase IIb trial for treatment-resistant depression, showing a significant reduction in MADRS scores.

Clearmind Medicine received IRB approval for its Phase I/IIa clinical trial of CMND-100, a novel therapeutic targeting alcohol use disorder (AUD).

Clearmind Medicine has secured IRB approval for its Phase I/IIa clinical trial of CMND-100, a MEAI-based treatment for alcohol use disorder (AUD).